• BioStem Technologies entered a committed equity facility for up to USD 40 million with Roth Principal Investments via a private placement.
• Facility lets BioStem sell common stock to Roth at its discretion, subject to conditions including an effective resale registration statement.
• Issuance is capped at 19.99% of shares outstanding at signing unless shareholder approval is obtained or Nasdaq minimum-price rules are met.
• Net proceeds are intended for working capital, general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biostem Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609180700PRIMZONEFULLFEED9829451) on September 18, 2026, and is solely responsible for the information contained therein.